GlassScriptPhysician profile
Rakesh Marwaha
NPI 1164539094
$16,470.85
in general payments reported to CMS, 2019-2025
81 companies · $2,419 in 2025
The $2,419 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,051 · 2020: $1,980 · 2021: $2,444 · 2022: $2,424 · 2023: $2,862 · 2024: $2,292 · 2025: $2,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,535 · Education: $36.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,535.19 |
| Education | $36.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,755.75 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Janssen Pharmaceuticals, INC | $1,157.36 | 2019-2025 | Spravato, Xarelto |
| Abbvie INC. | $1,125.58 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $979.29 | 2020-2023 | |
| Glaxosmithkline, LLC. | $930.06 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $896.63 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $863.40 | 2019-2025 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $844.26 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $830.55 | 2019-2025 | |
| Corcept Therapeutics | $661.56 | 2019-2023 | Korlym |
| Xeris Pharmaceuticals, INC. | $623.91 | 2022-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $584.35 | 2019-2025 | Jardiance, Synjardy, Glyxambi |
| Aimmune Therapeutics, INC. | $331.68 | 2024-2025 | Zenpep |
| Novartis Pharmaceuticals Corporation | $298.40 | 2019-2024 | |
| Kowa Pharmaceuticals America, INC. | $261.35 | 2022-2025 | Zoryve |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Marwaha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.